| Involvement of Brca2 in DNA repair KJ Patel, PCC Veronica, H Lee, A Corcoran, FC Thistlethwaite, MJ Evans, ... Molecular cell 1 (3), 347-357, 1998 | 804 | 1998 |
| Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019 | 417 | 2019 |
| The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent … FC Thistlethwaite, DE Gilham, RD Guest, DG Rothwell, M Pillai, DJ Burt, ... Cancer Immunology, Immunotherapy 66, 1425-1436, 2017 | 344 | 2017 |
| Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma C Ralph, E Elkord, DJ Burt, JF O'Dwyer, EB Austin, PL Stern, RE Hawkins, ... Clinical Cancer Research 16 (5), 1662-1672, 2010 | 299 | 2010 |
| Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding … TK Choueiri, J Larkin, M Oya, F Thistlethwaite, M Martignoni, P Nathan, ... The lancet oncology 19 (4), 451-460, 2018 | 272 | 2018 |
| Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2 H Lee, AH Trainer, LS Friedman, FC Thistlethwaite, MJ Evans, ... Molecular cell 4 (1), 1-10, 1999 | 241 | 1999 |
| Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ... Nature medicine 25 (5), 738-743, 2019 | 237 | 2019 |
| Thymic Lymphomas in Mice with a Truncating Mutation in Brca2 LS Friedman, FC Thistlethwaite, KJ Petel, VPCC Yu, H Lee, ... Cancer research 58 (7), 1338-1343, 1998 | 170 | 1998 |
| Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ... The lancet oncology 20 (3), 383-393, 2019 | 155 | 2019 |
| Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer N Tinsley, C Zhou, G Tan, S Rack, P Lorigan, F Blackhall, M Krebs, ... The oncologist 25 (1), 55-63, 2020 | 146 | 2020 |
| Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer DS Hong, N Concin, I Vergote, JS de Bono, BM Slomovitz, Y Drew, ... Clinical cancer research 26 (6), 1220-1228, 2020 | 96 | 2020 |
| Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells S Khan, DJ Burt, C Ralph, FC Thistlethwaite, RE Hawkins, E Elkord Clinical Immunology 138 (1), 85-96, 2011 | 77 | 2011 |
| A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ... Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018 | 71 | 2018 |
| Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-α RE Hawkins, C Macdermott, A Shablak, C Hamer, F Thistlethwaite, ... Journal of immunotherapy 32 (4), 424-429, 2009 | 56 | 2009 |
| A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). T Powles, JMG Larkin, P Patel, B Pérez-Valderrama, A Rodriguez-Vida, ... Journal of Clinical Oncology 37 (7_suppl), 545-545, 2019 | 55 | 2019 |
| High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer A Shablak, K Sikand, JH Shanks, F Thistlethwaite, A Spencer-Shaw, ... Journal of immunotherapy 34 (1), 107-112, 2011 | 55 | 2011 |
| First-line avelumab+ axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. TK Choueiri, JMG Larkin, M Oya, FC Thistlethwaite, M Martignoni, ... Journal of Clinical Oncology 35 (15_suppl), 4504-4504, 2017 | 52 | 2017 |
| Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma FC Thistlethwaite, E Elkord, RW Griffiths, DJ Burt, AM Shablak, ... Cancer Immunology, Immunotherapy 57, 623-634, 2008 | 42 | 2008 |
| Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial RD Guest, N Kirillova, S Mowbray, H Gornall, DG Rothwell, EJ Cheadle, ... Cancer Immunology, Immunotherapy 63, 133-145, 2014 | 40 | 2014 |
| Engineering T cells for cancer therapy W Mansoor, DE Gilham, FC Thistlethwaite, RE Hawkins British journal of cancer 93 (10), 1085-1091, 2005 | 38 | 2005 |
